{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:47:20Z","timestamp":1782841640930,"version":"3.54.5"},"reference-count":30,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The management of type 2 diabetes mellitus (T2DM) remains a complex clinical challenge, particularly for patients requiring multiple daily insulin injections (MDI). Advances in precision medicine and continuous glucose monitoring (CGM) have created opportunities to personalize treatment and potentially reduce the therapeutic burden on people with T2DM. Assessing \u03b2 cell function and autoimmunity could help identify patients with T2DM eligible for simplified regimens without compromising glycemic control.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The aim of this study is to test a simple personalized medicine protocol in routine clinical practice for people with T2DM treated with MDI. The intervention is based on evaluating C-peptide and glutamic acid decarboxylase autoantibody status with the goal of improving diagnostic accuracy and optimizing treatment.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This is a pragmatic before-and-after intervention study involving people with T2DM currently receiving MDI across primary care centers and a referral hospital in the Lleida health care region in Catalonia (Spain). Eligible participants will undergo clinical and laboratory assessment, including C-peptide and glutamic acid decarboxylase autoantibody testing, and wear a CGM device. On the basis of a predefined algorithm, patients may either continue or discontinue prandial insulin. The primary outcome is the proportion of patients in whom prandial insulin is discontinued and remains discontinued over 6 months. Secondary outcomes include changes in hemoglobin A\n 1c<\/jats:sub>\n , CGM metric variables, quality of life, adherence, and treatment satisfaction.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Recruitment was completed on March 31, 2025. The follow-up phase is ongoing and expected to conclude by September 30, 2025. Data analysis will begin thereafter.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study will evaluate the feasibility and impact of implementing a personalized therapeutic approach for persons with T2DM receiving MDI in real-world clinical settings. If effective, this strategy could contribute to safer, simpler, and more individualized diabetes care.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/85375","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:10:06Z","timestamp":1768835406000},"page":"e85375-e85375","source":"Crossref","is-referenced-by-count":2,"title":["Implementation of a Personalized Medicine Approach in Patients With Type 2 Diabetes Mellitus Receiving Multiple Daily Insulin Injections (POMA Project): Protocol for a Before-and-After Intervention Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6271-366X","authenticated-orcid":false,"given":"Rosa","family":"Gin\u00e9-Balcells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3768-8112","authenticated-orcid":false,"given":"Bogdan","family":"Vlacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7512-7417","authenticated-orcid":false,"given":"Olga Carmen","family":"Vidal-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9684-0183","authenticated-orcid":false,"given":"Albert","family":"Lecube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-1555","authenticated-orcid":false,"given":"Josep","family":"Franch-Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-0250","authenticated-orcid":false,"given":"D\u00eddac","family":"Mauricio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-0677","authenticated-orcid":false,"given":"\u00c0ngels","family":"Moll\u00f3-Iniesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1237-298X","authenticated-orcid":false,"given":"Marta","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"POMA Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"R1","unstructured":"IDF diabetes atlas. International Diabetes Federation. 2025. URL: https:\/\/diabetesatlas.org\/ [Accessed 25-05-2025]"},{"issue":"11","key":"R2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/diabetes.44.11.1249","article-title":"U.K. prospective diabetes study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. U.K. prospective diabetes study group","volume":"44","journal-title":"Diabetes"},{"issue":"1 Suppl 1","key":"R3","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","author":"ElSayed","journal-title":"Diabetes Care"},{"issue":"10","key":"R4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s00125-020-05211-7","article-title":"The clinical consequences of heterogeneity within and between different diabetes types","volume":"63","author":"Redondo","journal-title":"Diabetologia"},{"issue":"7","key":"R5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/dme.12700","article-title":"Latent autoimmune diabetes of the adult: current knowledge and uncertainty","volume":"32","author":"Laugesen","journal-title":"Diabet Med"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_533","article-title":"Latent autoimmune diabetes in adults: a review of clinically relevant issues","volume":"1307","author":"Hern\u00e1ndez","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"R7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281657","article-title":"Development and validation of a clinical score for identifying patients with high risk of latent autoimmune adult diabetes (LADA): the LADA primary care-protocol study","volume":"18","author":"Vich-P\u00e9rez","journal-title":"PLoS ONE"},{"issue":"6","key":"R8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4093\/dmj.2018.0190","article-title":"Latent autoimmune diabetes in adults: a review on clinical implications and management","volume":"42","author":"Pieralice","journal-title":"Diabetes Metab J"},{"issue":"4","key":"R9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2337\/dc11-1679","article-title":"Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain)","volume":"35","author":"Vinagre","journal-title":"Diabetes Care"},{"issue":"8","key":"R10","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25081987","article-title":"Type 2 diabetes mellitus: a review of multi-target drugs","volume":"25","author":"Artasensi","journal-title":"Molecules"},{"issue":"4","key":"R11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13300-022-01222-2","article-title":"Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes","volume":"13","author":"Jude","journal-title":"Diabetes Ther"},{"issue":"9","key":"R12","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14901","article-title":"Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes","volume":"39","author":"Mehta","journal-title":"Diabet Med"},{"issue":"12","key":"R13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","journal-title":"Diabetologia"},{"issue":"10","key":"R14","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1111\/dom.14785","article-title":"C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective","volume":"24","author":"Maddaloni","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"R15","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.2337\/dc19-2316","article-title":"Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial","volume":"43","author":"Rosenstock","journal-title":"Diabetes Care"},{"issue":"6","key":"R16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2337\/dc20-2623","article-title":"Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial","volume":"44","author":"Giugliano","journal-title":"Diabetes Care"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108958","article-title":"Simplification of complex insulin therapy: a story of dogma and therapeutic resignation","volume":"178","author":"Giugliano","journal-title":"Diabetes Res Clin Pract"},{"issue":"1 Suppl 1","key":"R18","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.2337\/dc25-S007","article-title":"7. Diabetes technology: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","journal-title":"Diabetes Care"},{"issue":"7","key":"R19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41574-024-00973-1","article-title":"Continuous glucose monitoring for the routine care of type 2 diabetes mellitus","volume":"20","author":"Ajjan","journal-title":"Nat Rev Endocrinol"},{"key":"R20","unstructured":"Model organitzatiu per a la prestaci\u00f3 dels sistemes de monitoratge continu de glucosa a pacients amb diabetis mellitus de tipus 2 al SISCAT. CatSalut: Servei Catal\u00e0 de la Salut. URL: https:\/\/scientiasalut.gencat.cat\/handle\/11351\/9917 [Accessed 25-05-2025]"},{"key":"R21","unstructured":"Convenience sampling method: how and when to use it? Qualtrics. URL: https:\/\/www.qualtrics.com\/experience-management\/research\/convenience-sampling\/ [Accessed 25-05-2025]"},{"issue":"8","key":"R22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0212-6567(02)70623-9","article-title":"Quality-of-life questionnaire designed for diabetes mellitus (EsDQOL)","volume":"29","author":"Millan","journal-title":"Aten Primaria"},{"key":"R23","unstructured":"Bradley C . Diabetes treatment satisfaction questionnaire: (DTSQ). In: Bradley C , editor. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Routledge; 1994. ISBN: 9783718655625"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1524-4733.2008.00400.x","article-title":"Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease","volume":"12","author":"Kripalani","journal-title":"Value Health"},{"issue":"8","key":"R25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Craig","journal-title":"Med Sci Sports Exerc"},{"key":"R26","unstructured":"Resoluci\u00f3n de 7 de abril de 2022, de la direcci\u00f3n general de cartera com\u00fan de servicios del sistema nacional de salud y farmacia, por la que se hace p\u00fablico el acuerdo de la comisi\u00f3n de prestaciones, aseguramiento y financiaci\u00f3n de 2 de marzo de 2022 sobre sistema de monitorizaci\u00f3n de glucosa para pacientes con diabetes mellitus tipo 2 en la cartera com\u00fan de servicios del sistema nacional de salud. Ministerio de Sanidad; 2022. URL: https:\/\/www.sanidad.gob.es\/ca\/profesionales\/prestacionesSanitarias\/CarteraDeServicios\/ContenidoCS\/docs\/Resoluc_DG__DM2_DEF.pdf [Accessed 20-02-2026]"},{"key":"R27","unstructured":"Diabetes trials unit: HOMA calculator. University of Oxford. URL: https:\/\/www.dtu.ox.ac.uk\/homacalculator\/ [Accessed 25-05-2025]"},{"issue":"10480","key":"R28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0140-6736(24)02617-5","article-title":"A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study","volume":"405","author":"Dennis","journal-title":"The Lancet"},{"issue":"9922","key":"R29","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","article-title":"The many faces of diabetes: a disease with increasing heterogeneity","volume":"383","author":"Tuomi","journal-title":"The Lancet"},{"issue":"3","key":"R30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/a-1242-9809","article-title":"Considering insulin secretory capacity as measured by a fasting C-peptide\/glucose ratio in selecting glucose-lowering medications","volume":"130","author":"Fritsche","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e85375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:13:42Z","timestamp":1782839622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e85375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2196\/85375","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"v15i11e85375"}}